Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc

<< Previous

Bullboard Posts

Next >>

Post by dexiieeon Jan 07, 2021 8:39am

98 Views

Post# 32240536

Sponsored Post: Annual Growth

The global market for legal cannabis is said to be already worth billions. Estimates of growth have been so wildly optimistic that some fear a speculative bubble may burst around the industrialization of green gold. That's a great read, very insightful! You should check out!

Studies estimate annual growth for the coming years to be between 24 and 30 per cent. Approximately US$12 billion in 2019, the market could increase to US$130 billion by 2029, according to the most optimistic. Other, more cautious experts estimate it at around US$50 billion if the legal landscape remains unchanged between now and then which look unlikely given the current progression of legislation.

The evolution of medical and pharmaceutical research is not unrelated to this more and more countries are moving towards therapeutic, and even recreational cannabis.Check the disclaimer on the profile and landing page.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market